Upregulation of pentraxin-3 in human endothelial cells after lysophosphatidic acid exposure

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 3, 2008, Pages 491-497

  Gustin, Cindy ^a   Delaive, Edouard ^a   Dieu, Marc ^a   Calay, Damien ^a   Raes, Martine ^a  

^a UNIVERSITY OF NAMUR   (Belgium)

Author keywords

Atherosclerosis; Chemoattractant; Endothelial cell; Lysophosphatidic acid; Phentraxin 3

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; PENTRAXIN 3; POLYPEPTIDE; C REACTIVE PROTEIN; LYSOPHOSPHOLIPID; SERUM AMYLOID P;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL ASSAY; CELL IMMORTALIZATION; CHEMOTAXIS; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MONOCYTE; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEOMICS; UPREGULATION; ANALYSIS OF VARIANCE; CELL CULTURE; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOBLOTTING; METABOLISM; PATHOPHYSIOLOGY; PROBABILITY; SECRETION; SENSITIVITY AND SPECIFICITY; UMBILICAL VEIN;

ANALYSIS OF VARIANCE; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOBLOTTING; LYSOPHOSPHOLIPIDS; PROBABILITY; RECEPTORS, LYSOPHOSPHATIDIC ACID; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SERUM AMYLOID P-COMPONENT; UMBILICAL VEINS; UP-REGULATION;

EID: 40749088919     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.158642     Document Type: Article

References (37)

1. Hansson GK. Regulation of immune mechanisms in atherosclerosis. Ann N Y Acad Sci. 2001;947:157-165; discussion 165-156.
2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365-372.
3. Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med. 2001;11:142-147.
4. Siess W, Zangl KJ, Essler M, Bauer M, Brandl R, Corrinth C, Bittman R, Tigyi G, Aepfelbacher M. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A. 1999;96:6931-6936.
5. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phos-pholipid lysophosphatidic acid is released from activated platelets. Biochem J. 1993;291(Pt 3):677-680.
6. Tokumura A, Iimori M, Nishioka Y, Kitahara M, Sakashita M, Tanaka S. Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. Am J Physiol. 1994;267:C204-C210.
7. Moolenaar WH. Development of our current understanding of bioactive lysophospholipids. Ann N Y Acad Sci. 2000;905:1-10.
8. Meyer zu Heringdorf D, Jakobs KH. Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta. 2007;1768:923-940.
9. McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, Hinshaw JC, Zimmerman GA, Hama K, Aoki J, Arai H, Prestwich GD. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci U S A. 2003;100: 131-136.
10. Gerrard JM, Kindom SE, Peterson DA, Peller J, Krantz KE, White JG. Lysophosphatidic acids. Influence on platelet aggregation and intra-cellular calcium flux. Am J Pathol. 1979;96:423-438.
11. Zhou D, Luini W, Bernasconi S, Diomede L, Salmona M, Mantovani A, Sozzani S. Phosphatidic acid and lysophosphatidic acid induce hapto-tactic migration of human monocytes. J Biol Chem. 1995;270: 25549-25556.
12. Koh JS, Lieberthal W, Heydrick S, Levine JS. Lysophosphatidic acid is a major serum noncytokine survival factor for murine macrophages which acts via the phosphatidylinositol 3-kinase signaling pathway. J Clin Invest. 1998;102:716-727.
13. Rizza C, Leitinger N, Yue J, Fischer DJ, Wang DA, Shih PT, Lee H, Tigyi G, Berliner JA. Lysophosphatidic acid as a regulator of endotheli-al/leukocyte interaction. Lab Invest. 1999;79:1227-1235.
14. Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol. 1993;150:1804-1812.
15. Lee TH, Lee GW, Ziff EB, Vilcek J. Isolation and characterization of eight tumor necrosis factor-induced gene sequences from human fibro-blasts. Mol Cell Biol. 1990;10:1982-1988.
16. Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, Saccone S, Marzella R, Predazzi V, Rocchi M, et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem. 1992; 267:22190-22197.
17. Luchetti MM, Piccinini G, Mantovani A, Peri G, Matteucci C, Pomponio G, Fratini M, Fraticelli P, Sambo P, Di Loreto C, Doni A, Introna M, Gabrielli A. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol. 2000;119:196-202.
18. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood. 1994;84:3483-3493.
19. Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G, Spreafico F, Pausa M, D'Ettorre C, Gianazza E, Tagliabue A, Salmona M, Tedesco F, Introna M, Mantovani A. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem. 1997;272:32817-32823.
20. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22:e10-e14.
21. Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G, Mantovani A. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis. 2004;175:221-228.
22. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, Vago L, Pasqualini F, Signorini S, Soldateschi D, Tarli L, Schweiger C, Fresco C, Cecere R, Tognoni G, Mantovani A. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004; 110:2349-2354.
23. Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J, Kimura T, Tobo M, Yamazaki Y, Watanabe T, Yagi M, Sato M, Suzuki R, Murooka H, Sakai T, Nishitoba T, Im DS, Nochi H, Tamoto K, Tomura H, Okajima F. Ki16425, a subtype-selective antagonist for EDG-family lysophos-phatidic acid receptors. Mol Pharmacol. 2003;64:994-1005.
24. Renard P, Ernest I, Houbion A, Art M, Le Calvez H, Raes M, Remacle J. Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res. 2001;29:e21.
25. Takada Y, Kobayashi Y, Aggarwal BB. Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptot-ic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J Biol Chem. 2005;280:17203-17212.
26. Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol. 2007; 27:266-274.
27. Moolenaar WH, Kruijer W, Tilly BC, Verlaan I, Bierman AJ, de Laat SW. Growth factor-like action of phosphatidic acid. Nature. 1986;323: 171-173.
28. Siess W. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta. 2002;1582: 204-215.
29. Bouis D, Hospers GA, Meijer C, Molema G, Mulder NH. Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis. 2001;4:91-102.
30. Suggs JE, Madden MC, Friedman M, Edgell CJ. Prostacyclin expression by a continuous human cell line derived from vascular endothelium. Blood. 1986;68:825-829.
31. Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci U S A. 1983;80:3734-3737.
32. Lin CI, Chen CN, Chen JH, Lee H. Lysophospholipids increase IL-8 and MCP-1 expressions in human umbilical cord vein endothelial cells through an IL-1-dependent mechanism. J Cell Biochem. 2006;99: 1216-1232.
33. Cook SJ, McCormick F. Kinetic and biochemical correlation between sustained p44ERK1 (44 kDa extracellular signal-regulated kinase 1) activation and lysophosphatidic acid-stimulated DNA synthesis in Rat-1 cells. Biochem J. 1996;320(Pt 1):237-245.
34. Cook SJ, Aziz N, McMahon M. The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation. Mol Cell Biol. 1999;19:330-341.
35. Motohashi K, Shibata S, Ozaki Y, Yatomi Y, Igarashi Y. Identification of lysophospholipid receptors in human platelets: the relation of two agonists, lysophosphatidic acid and sphingosine 1-phosphate. FEBS Lett. 2000;468:189-193.
36. Basile A, Sica A, d'Aniello E, Breviario F, Garrido G, Castellano M, Mantovani A, Introna M. Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. J Biol Chem. 1997;272: 8172-8178.
37. Han KH, Hong KH, Park JH, Ko J, Kang DH, Choi KJ, Hong MK, Park SW, Park SJ. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation. 2004;109: 2566-2571.